Sep / 2025

OncoDaily IO OncoDaily GI Hemostasis Today

Insight

Oct 23, 2023 5:15 pm

Oct 23, 2023 3:26 pm

Oct 23, 2023 3:24 pm

Oct 23, 2023 1:26 pm

Oct 22, 2023 6:11 pm

Oct 22, 2023 5:06 pm

Oct 21, 2023 7:04 pm

Oct 20, 2023 8:13 pm

Oct 20, 2023 8:12 pm

Oct 20, 2023 8:06 pm

…

771

…

Insight

María Natalia Gandur Quiroga: Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results

Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)

Why radiotherapy with concomitant chemotherapy is an excellent option for bladder preservation in bladder cancer patients

Marcelo Corassa: Great presentation by the amazing Jarushka Naidoo on the promises and pitfalls of neoadjuvant therapy for NSCLC

Katrina Pedersen: Not many people realize that there is NO prospective interventional trial data for FOLFIRI or for a powered Taxane cohort in Small Bowel Adenocarcinoma

Julia Hoveyan: The first comprehensive analysis of pediatric and young adult CNS tumors in Armenia over the last 26 years

Sharlene Gill’s summary of KEYNOTE-811 by Yelena Janjigian from ESMO23

Aman Chauhan: We will continue to work on NEC and SCLC and hopefully find a breakthrough

Vanina Laurent-Ledru: 4 key take-aways from the session on implementing One Health at the World Health Summit in Berlin

Nina Niu Sanford: Our work on clinical trial endpoints and inclusion criteria in GI oncology trials

Headlines

Insight

María Natalia Gandur Quiroga: Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results

Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)

Why radiotherapy with concomitant chemotherapy is an excellent option for bladder preservation in bladder cancer patients

Marcelo Corassa: Great presentation by the amazing Jarushka Naidoo on the promises and pitfalls of neoadjuvant therapy for NSCLC

Katrina Pedersen: Not many people realize that there is NO prospective interventional trial data for FOLFIRI or for a powered Taxane cohort in Small Bowel Adenocarcinoma

Julia Hoveyan: The first comprehensive analysis of pediatric and young adult CNS tumors in Armenia over the last 26 years

Sharlene Gill’s summary of KEYNOTE-811 by Yelena Janjigian from ESMO23

Aman Chauhan: We will continue to work on NEC and SCLC and hopefully find a breakthrough

Vanina Laurent-Ledru: 4 key take-aways from the session on implementing One Health at the World Health Summit in Berlin

Nina Niu Sanford: Our work on clinical trial endpoints and inclusion criteria in GI oncology trials

Headlines

OncoDaily

Oncology

cancer

fight against cancer

Global fight against cancer

cancer care

Breast Cancer

ASCO

Lung cancer

Cancer research

MD Anderson Cancer Center

cancer awareness

NSCLC

ESMO

immunotherapy

cancer treatment

Research

ASCO24

Headlines

colorectal cancer

Childhood Cancer

prostate cancer

AACR

clinical trials

FDA

Dana-Farber Cancer Institute

UICC

American Cancer Society

European Cancer Organisation

NCI

National Cancer Institute

healthcare

SIOP

ASCO25

chemotherapy

Vivek Subbiah

AI

American Society of Clinical Oncology

Paolo Tarantino

IASLC

WHO

Robert Orlowski

multiple myeloma

Memorial Sloan Kettering Cancer Center

Zainab Shinkafi-Bagudu

radiation oncology

Myeloma Paper of the Day

cervical cancer

Myeloma

patient care

European School of Oncology

Sitemap